ID   WEE1_HUMAN              Reviewed;         646 AA.
AC   P30291; B3KVE1; D3DQV0;
DT   01-APR-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1996, sequence version 2.
DT   15-MAR-2017, entry version 184.
DE   RecName: Full=Wee1-like protein kinase;
DE            Short=WEE1hu;
DE            EC=2.7.10.2;
DE   AltName: Full=Wee1A kinase;
GN   Name=WEE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND CHARACTERIZATION.
RX   PubMed=7743995;
RA   Watanabe N., Broome M., Hunter T.;
RT   "Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell
RT   cycle.";
RL   EMBO J. 14:1878-1891(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=11528126;
RA   Cichutek A., Brueckmann T., Seipel B., Hauser H., Schlaubitz S.,
RA   Prawitt D., Hankeln T., Schmidt E.R., Winterpacht A., Zabel B.U.;
RT   "Comparative architectural aspects of regions of conserved synteny on
RT   human chromosome 11p15.3 and mouse chromosome 7 (including genes WEE1
RT   and LMO1).";
RL   Cytogenet. Cell Genet. 93:277-283(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Amygdala;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-214 (ISOFORM 1).
RA   Igarashi M.;
RL   Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 215-646 (ISOFORM 1).
RX   PubMed=1840647; DOI=10.1038/353080a0;
RA   Igarashi M., Nagata A., Jinno S., Suto K., Okayama H.;
RT   "Wee1(+)-like gene in human cells.";
RL   Nature 353:80-83(1991).
RN   [8]
RP   CHARACTERIZATION, AND MUTAGENESIS OF LYS-328.
RX   PubMed=8428596;
RA   McGowan C.H., Russell P.;
RT   "Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2
RT   exclusively on Tyr15.";
RL   EMBO J. 12:75-85(1993).
RN   [9]
RP   PHOSPHORYLATION AT SER-642.
RC   TISSUE=Testis;
RX   PubMed=15150265; DOI=10.1074/jbc.M404728200;
RA   Lu R., Niida H., Nakanishi M.;
RT   "Human SAD1 kinase is involved in UV-induced DNA damage checkpoint
RT   function.";
RL   J. Biol. Chem. 279:31164-31170(2004).
RN   [10]
RP   PHOSPHORYLATION AT SER-53 AND SER-123, UBIQUITINATION, AND MUTAGENESIS
RP   OF SER-53; 116-GLU-GLU-117 AND SER-123.
RX   PubMed=15070733; DOI=10.1073/pnas.0307700101;
RA   Watanabe N., Arai H., Nishihara Y., Taniguchi M., Watanabe N.,
RA   Hunter T., Osada H.;
RT   "M-phase kinases induce phospho-dependent ubiquitination of somatic
RT   Wee1 by SCFbeta-TrCP.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:4419-4424(2004).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-150; THR-190 AND
RP   SER-312, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-139, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION AT SER-642, AND MUTAGENESIS OF SER-642.
RX   PubMed=20026642; DOI=10.1242/jcs.058230;
RA   Muller M., Lutter D., Puschel A.W.;
RT   "Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and
RT   SadB-deficient neurons disrupts neuronal polarity.";
RL   J. Cell Sci. 123:286-294(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-127 AND SER-139, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [16]
RP   PHOSPHORYLATION AT THR-239, AND DEPHOSPHORYLATION.
RX   PubMed=22692537; DOI=10.1038/ncomms1886;
RA   Visconti R., Palazzo L., Della Monica R., Grieco D.;
RT   "Fcp1-dependent dephosphorylation is required for M-phase-promoting
RT   factor inactivation at mitosis exit.";
RL   Nat. Commun. 3:894-894(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-137; SER-139; THR-187;
RP   THR-190; SER-270; SER-307 AND SER-312, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (1.81 ANGSTROMS) OF 291-575 IN COMPLEX WITH
RP   MAGNESIUM AND AN INHIBITOR.
RX   PubMed=15837193; DOI=10.1016/j.str.2004.12.017;
RA   Squire C.J., Dickson J.M., Ivanovic I., Baker E.N.;
RT   "Structure and inhibition of the human cell cycle checkpoint kinase,
RT   Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1
RT   regulation.";
RL   Structure 13:541-550(2005).
RN   [19]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-210 AND ILE-472.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Acts as a negative regulator of entry into mitosis (G2
CC       to M transition) by protecting the nucleus from cytoplasmically
CC       activated cyclin B1-complexed CDK1 before the onset of mitosis by
CC       mediating phosphorylation of CDK1 on 'Tyr-15'. Specifically
CC       phosphorylates and inactivates cyclin B1-complexed CDK1 reaching a
CC       maximum during G2 phase and a minimum as cells enter M phase.
CC       Phosphorylation of cyclin B1-CDK1 occurs exclusively on 'Tyr-15'
CC       and phosphorylation of monomeric CDK1 does not occur. Its activity
CC       increases during S and G2 phases and decreases at M phase when it
CC       is hyperphosphorylated. A correlated decrease in protein level
CC       occurs at M/G1 phase, probably due to its degradation.
CC   -!- CATALYTIC ACTIVITY: ATP + a [protein]-L-tyrosine = ADP + a
CC       [protein]-L-tyrosine phosphate. {ECO:0000255|PROSITE-
CC       ProRule:PRU10027}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC       Note=Binds 2 magnesium ions per subunit.;
CC   -!- ENZYME REGULATION: Synthesis is increased during S and G2 phases,
CC       presumably by an increase in transcription; activity is decreased
CC       by phosphorylation during m phase. Protein levels fall in M phase
CC       as a result of decreased synthesis combined with degradation.
CC       Activity seems to be negatively regulated by phosphorylation upon
CC       entry into mitosis, although N-terminal phosphorylation might also
CC       regulate the protein stability via protection from proteolysis or
CC       might regulate the subcellular location.
CC   -!- INTERACTION:
CC       Q9Y297:BTRC; NbExp=2; IntAct=EBI-914695, EBI-307461;
CC       Q9UKB1:FBXW11; NbExp=3; IntAct=EBI-914695, EBI-355189;
CC       P63104:YWHAZ; NbExp=3; IntAct=EBI-914695, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Nucleus.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P30291-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P30291-2; Sequence=VSP_044959;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Phosphorylated during M and G1 phases. Also
CC       autophosphorylated. Phosphorylation at Ser-642 by BRSK1 and BRSK2
CC       in post-mitotic neurons, leads to down-regulate WEE1 activity in
CC       polarized neurons. Phosphorylated at Ser-53 and Ser-123 by PLK1
CC       and CDK1, respectively, generating an signal for degradation that
CC       can be recognized by the SCF(BTRC) complex, leading to its
CC       ubiquitination and degradation at the onset of G2/M phase.
CC       {ECO:0000269|PubMed:15070733, ECO:0000269|PubMed:15150265,
CC       ECO:0000269|PubMed:20026642, ECO:0000269|PubMed:22692537}.
CC   -!- PTM: Dephosphorylated at Thr-239 by CTDP1.
CC   -!- PTM: Ubiquitinated and degraded at the onset of G2/M phase.
CC       {ECO:0000269|PubMed:15070733}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Ser/Thr
CC       protein kinase family. WEE1 subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U10564; AAB60401.1; -; mRNA.
DR   EMBL; AJ277546; CAC14173.1; -; Genomic_DNA.
DR   EMBL; AK122837; BAG53753.1; -; mRNA.
DR   EMBL; AC011979; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC122179; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68586.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68587.1; -; Genomic_DNA.
DR   EMBL; CH471064; EAW68588.1; -; Genomic_DNA.
DR   EMBL; X62048; CAA43979.1; -; mRNA.
DR   CCDS; CCDS44536.1; -. [P30291-2]
DR   CCDS; CCDS7800.1; -. [P30291-1]
DR   PIR; S55048; S55048.
DR   RefSeq; NP_001137448.1; NM_001143976.1. [P30291-2]
DR   RefSeq; NP_003381.1; NM_003390.3. [P30291-1]
DR   UniGene; Hs.249441; -.
DR   PDB; 1X8B; X-ray; 1.81 A; A=291-575.
DR   PDB; 2IN6; X-ray; 1.90 A; A=291-575.
DR   PDB; 2IO6; X-ray; 2.20 A; A=291-575.
DR   PDB; 2Z2W; X-ray; 2.22 A; A=291-575.
DR   PDB; 3BI6; X-ray; 2.20 A; A=291-575.
DR   PDB; 3BIZ; X-ray; 2.20 A; A=291-575.
DR   PDB; 3CQE; X-ray; 2.50 A; A=291-575.
DR   PDB; 3CR0; X-ray; 2.30 A; A=291-575.
DR   PDBsum; 1X8B; -.
DR   PDBsum; 2IN6; -.
DR   PDBsum; 2IO6; -.
DR   PDBsum; 2Z2W; -.
DR   PDBsum; 3BI6; -.
DR   PDBsum; 3BIZ; -.
DR   PDBsum; 3CQE; -.
DR   PDBsum; 3CR0; -.
DR   DisProt; DP00611; -.
DR   ProteinModelPortal; P30291; -.
DR   SMR; P30291; -.
DR   BioGrid; 113303; 32.
DR   DIP; DIP-37969N; -.
DR   IntAct; P30291; 18.
DR   MINT; MINT-129561; -.
DR   STRING; 9606.ENSP00000402084; -.
DR   BindingDB; P30291; -.
DR   ChEMBL; CHEMBL5491; -.
DR   GuidetoPHARMACOLOGY; 2278; -.
DR   iPTMnet; P30291; -.
DR   PhosphoSitePlus; P30291; -.
DR   BioMuta; WEE1; -.
DR   DMDM; 1351419; -.
DR   EPD; P30291; -.
DR   MaxQB; P30291; -.
DR   PaxDb; P30291; -.
DR   PeptideAtlas; P30291; -.
DR   PRIDE; P30291; -.
DR   DNASU; 7465; -.
DR   Ensembl; ENST00000299613; ENSP00000299613; ENSG00000166483. [P30291-2]
DR   Ensembl; ENST00000450114; ENSP00000402084; ENSG00000166483. [P30291-1]
DR   GeneID; 7465; -.
DR   KEGG; hsa:7465; -.
DR   UCSC; uc001mhs.4; human. [P30291-1]
DR   CTD; 7465; -.
DR   DisGeNET; 7465; -.
DR   GeneCards; WEE1; -.
DR   HGNC; HGNC:12761; WEE1.
DR   HPA; CAB004619; -.
DR   HPA; HPA068845; -.
DR   MIM; 193525; gene.
DR   neXtProt; NX_P30291; -.
DR   OpenTargets; ENSG00000166483; -.
DR   PharmGKB; PA366; -.
DR   eggNOG; KOG0601; Eukaryota.
DR   eggNOG; ENOG410XS1M; LUCA.
DR   GeneTree; ENSGT00530000063230; -.
DR   HOGENOM; HOG000004824; -.
DR   HOVERGEN; HBG005050; -.
DR   InParanoid; P30291; -.
DR   KO; K06632; -.
DR   OMA; WNDSCGE; -.
DR   OrthoDB; EOG091G049H; -.
DR   PhylomeDB; P30291; -.
DR   TreeFam; TF101088; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   Reactome; R-HSA-156711; Polo-like kinase mediated events.
DR   Reactome; R-HSA-69202; Cyclin E associated events during G1/S transition.
DR   Reactome; R-HSA-69273; Cyclin A/B1 associated events during G2/M transition.
DR   Reactome; R-HSA-69478; G2/M DNA replication checkpoint.
DR   Reactome; R-HSA-69656; Cyclin A:Cdk2-associated events at S phase entry.
DR   Reactome; R-HSA-75035; Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; P30291; -.
DR   SIGNOR; P30291; -.
DR   ChiTaRS; WEE1; human.
DR   EvolutionaryTrace; P30291; -.
DR   GeneWiki; Wee1-like_protein_kinase; -.
DR   GenomeRNAi; 7465; -.
DR   PMAP-CutDB; P30291; -.
DR   PRO; PR:P30291; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000166483; -.
DR   CleanEx; HS_WEE1; -.
DR   ExpressionAtlas; P30291; baseline and differential.
DR   Genevisible; P30291; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; TAS:ProtInc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:InterPro.
DR   GO; GO:0004715; F:non-membrane spanning protein tyrosine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; TAS:ProtInc.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; TAS:Reactome.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0007067; P:mitotic nuclear division; IEA:UniProtKB-KW.
DR   GO; GO:0048812; P:neuron projection morphogenesis; IEA:Ensembl.
DR   GO; GO:0051726; P:regulation of cell cycle; TAS:Reactome.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR017164; Wee1-like_protein_kinase.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF037281; Wee1-like_protein_kinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle;
KW   Cell division; Complete proteome; Kinase; Magnesium; Metal-binding;
KW   Mitosis; Nucleotide-binding; Nucleus; Phosphoprotein; Polymorphism;
KW   Reference proteome; Transferase; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   CHAIN         1    646       Wee1-like protein kinase.
FT                                /FTId=PRO_0000086810.
FT   DOMAIN      299    569       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     305    313       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS      9     12       Poly-Pro.
FT   COMPBIAS     34     43       Poly-Glu.
FT   ACT_SITE    426    426       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL       431    431       Magnesium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15837193}.
FT   METAL       463    463       Magnesium; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:15837193}.
FT   BINDING     328    328       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES      53     53       Phosphoserine; by PLK1.
FT                                {ECO:0000269|PubMed:15070733}.
FT   MOD_RES      78     78       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q63802}.
FT   MOD_RES      85     85       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     123    123       Phosphoserine; by CDK1.
FT                                {ECO:0000269|PubMed:15070733}.
FT   MOD_RES     127    127       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231}.
FT   MOD_RES     137    137       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     139    139       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     150    150       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P47810}.
FT   MOD_RES     187    187       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     190    190       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     239    239       Phosphothreonine.
FT                                {ECO:0000269|PubMed:22692537}.
FT   MOD_RES     270    270       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     307    307       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     312    312       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     642    642       Phosphoserine; by BRSK1 and BRSK2.
FT                                {ECO:0000269|PubMed:15150265,
FT                                ECO:0000269|PubMed:20026642}.
FT   VAR_SEQ       1    214       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044959.
FT   VARIANT     210    210       G -> C (in dbSNP:rs34412975).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041302.
FT   VARIANT     472    472       S -> I (in dbSNP:rs56411856).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041303.
FT   MUTAGEN      53     53       S->A: Abolishes phosphorylation by PLK1
FT                                and CDK1 and binding of the SCF(BTRC)
FT                                complex, leading to stabilization of the
FT                                protein; when associated with A-123.
FT                                {ECO:0000269|PubMed:15070733}.
FT   MUTAGEN     116    117       EE->AA: Impairs binding of the SCF(BTRC)
FT                                complex. {ECO:0000269|PubMed:15070733}.
FT   MUTAGEN     123    123       S->A: Abolishes phosphorylation by PLK1
FT                                and CDK1 and binding of the SCF(BTRC)
FT                                complex, leading to stabilization of the
FT                                protein; when associated with A-53.
FT                                {ECO:0000269|PubMed:15070733}.
FT   MUTAGEN     328    328       K->R: Abolishes activity.
FT                                {ECO:0000269|PubMed:8428596}.
FT   MUTAGEN     642    642       S->A: Abolishes phosphorylation by BRSK1
FT                                and BRSK2. {ECO:0000269|PubMed:20026642}.
FT   CONFLICT     65     65       A -> E (in Ref. 6; CAA43979).
FT                                {ECO:0000305}.
FT   HELIX       294    298       {ECO:0000244|PDB:1X8B}.
FT   STRAND      299    308       {ECO:0000244|PDB:1X8B}.
FT   STRAND      311    318       {ECO:0000244|PDB:1X8B}.
FT   TURN        319    321       {ECO:0000244|PDB:1X8B}.
FT   STRAND      324    331       {ECO:0000244|PDB:1X8B}.
FT   STRAND      335    337       {ECO:0000244|PDB:2Z2W}.
FT   HELIX       338    352       {ECO:0000244|PDB:1X8B}.
FT   STRAND      362    368       {ECO:0000244|PDB:1X8B}.
FT   STRAND      371    377       {ECO:0000244|PDB:1X8B}.
FT   HELIX       384    394       {ECO:0000244|PDB:1X8B}.
FT   HELIX       400    419       {ECO:0000244|PDB:1X8B}.
FT   HELIX       429    431       {ECO:0000244|PDB:1X8B}.
FT   STRAND      432    435       {ECO:0000244|PDB:1X8B}.
FT   STRAND      458    461       {ECO:0000244|PDB:1X8B}.
FT   HELIX       464    466       {ECO:0000244|PDB:3CQE}.
FT   HELIX       480    482       {ECO:0000244|PDB:1X8B}.
FT   HELIX       485    488       {ECO:0000244|PDB:1X8B}.
FT   HELIX       495    510       {ECO:0000244|PDB:1X8B}.
FT   STRAND      518    520       {ECO:0000244|PDB:1X8B}.
FT   HELIX       521    527       {ECO:0000244|PDB:1X8B}.
FT   HELIX       540    549       {ECO:0000244|PDB:1X8B}.
FT   HELIX       554    556       {ECO:0000244|PDB:1X8B}.
FT   HELIX       560    564       {ECO:0000244|PDB:1X8B}.
FT   HELIX       567    569       {ECO:0000244|PDB:3BI6}.
SQ   SEQUENCE   646 AA;  71597 MW;  DB00623D304562A0 CRC64;
     MSFLSRQQPP PPRRAGAACT LRQKLIFSPC SDCEEEEEEE EEEGSGHSTG EDSAFQEPDS
     PLPPARSPTE PGPERRRSPG PAPGSPGELE EDLLLPGACP GADEAGGGAE GDSWEEEGFG
     SSSPVKSPAA PYFLGSSFSP VRCGGPGDAS PRGCGARRAG EGRRSPRPDH PGTPPHKTFR
     KLRLFDTPHT PKSLLSKARG IDSSSVKLRG SSLFMDTEKS GKREFDVRQT PQVNINPFTP
     DSLLLHSSGQ CRRRKRTYWN DSCGEDMEAS DYELEDETRP AKRITITESN MKSRYTTEFH
     ELEKIGSGEF GSVFKCVKRL DGCIYAIKRS KKPLAGSVDE QNALREVYAH AVLGQHSHVV
     RYFSAWAEDD HMLIQNEYCN GGSLADAISE NYRIMSYFKE AELKDLLLQV GRGLRYIHSM
     SLVHMDIKPS NIFISRTSIP NAASEEGDED DWASNKVMFK IGDLGHVTRI SSPQVEEGDS
     RFLANEVLQE NYTHLPKADI FALALTVVCA AGAEPLPRNG DQWHEIRQGR LPRIPQVLSQ
     EFTELLKVMI HPDPERRPSA MALVKHSVLL SASRKSAEQL RIELNAEKFK NSLLQKELKK
     AQMAKAAAEE RALFTDRMAT RSTTQSNRTS RLIGKKMNRS VSLTIY
//
